HIV in the United Kingdom

Similar documents
Dr Alison Brown. Public Health England. 15 th Annual Conference of the National HIV Nurses Association (NHIVNA)

HIV testing in England and the NICE Quality Standards

HIV transmission in the UK within Black African communities: how common is it and how do we prevent it? Dr Valerie Delpech

Improving outcomes The UK s achievements in managing and preventing the HIV epidemic and how we should approach public health priorities

THIRD JOINT CONFERENCE OF BHIVA AND BASHH Dr Zheng Yin. Public Health England. 1-4 April 2014, Arena and Convention Centre Liverpool

Data on trans people and HIV in the UK

Towards elimination of HIV transmission, AIDS and HIV-related deaths in the UK

Annual Epidemiological Spotlight on HIV in London data

MANITOBA HIV REPORT 2015

HIV in the United Kingdom: 2009 Report

2020 Vision: making England s HIV prevention response the best in the world

NO DISCLOSURES TO DECLARE

HIV prevention: developments since 2012

When PrEP fails. Laura Waters MD FRCP Mortimer Market Centre London

Implementation of testing (and other interventions along the Continuum of Care)

Treatment as prevention (TasP) Can treatment reduce the transmission of HIV: Experience from the UK

Getting to Zero in California: Integration of HIV Prevention and Surveillance

Mortimer Market Centre, London. Dr Margaret Portman. Date : September 2016

ECDC and Spanish Ministry of Health workshop:

Treat All : From Policy to Action - What will it take?

Why are the targets a game-changer? What is the Fast-Track Cities Initiative and its connection to ?

HIV, HBV and HCV testing policy experiences and lessons learned.

Ending the Epidemic in New York State

Infectious Diseases and Sexual Health in Southwark

HIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE

Annual Epidemiological Report

Arizona State Office of Rural Health Webinar Series

HIV surveillance in Northern Ireland 2016

Regional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model

Epidemiologic Trends in HIV in Illinois. Prepared by Cheryl Ward for the 24 th Annual Illinois HIV/STD Conference

The REACH project: Factors associated with intervals between women s visits to HIV outpatient clinics

GLOBAL AIDS MONITORING REPORT

Connecting the Community. Advancing the HIV Response in Baltimore and Jackson.

Miami-Dade County Getting to Zero HIV/AIDS Task Force Implementation Report

ViiV Healthcare s Position on Prevention in HIV

London Pathway Evaluation

HIV testing in black Africans living in England

Hepatitis C Strategy. About us. What is hepatitis C?

Country Assessments to Strengthen Adolescent Component of National HIV Programme

Ending HIV and Australia s success story in PrEP implementation Dr Heather-Marie Schmidt

Towards universal access

Zero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium

Bruce D. Agins, MD MPH Medical Director, AIDS Institute Adherence 2017; Miami

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

HIV in Ireland 2016 Report

HUMAN SERVICES COMMISSION JANUARY 8, 2019 UNFINISHED BUSINESS HIV ZERO INITIATIVE END OF YEAR 2 EVALUATION REPORT

I know it because I live it An In-clinic peer mentorship scheme to improve outcomes in adolescents living with HIV

Bobby Goldsmith Foundation Strategic Plan

ACCELERATING HIV COMBINATION PREVENTION HIV COMBINATION PREVENTION INTERVENTIONS

HIV EPIDEMIOLOGY IN NEW YORK CITY

World Health Organization. A Sustainable Health Sector

Good care for people with HIV. Rights and Wrongs. Jane Anderson. May 2013

Suicide among people diagnosed with HIV in England and Wales compared to the general population

PrEP (Pre-Exposure-Prophylaxis) for sub-saharan African migrants in Europe?

Optimal HIV testing strategies to achieve high levels of HIV diagnosis in South Africa

National HIV/AIDS Strategy

London Pathway Evaluation

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017

Monitoring Recent HIV Infection in Ireland, 2017

HIV Treatment as Prevention (TasP)

NATIONAL SURVEY OF YOUNG ADULTS ON HIV/AIDS

From Africa to Georgia: What We Have Learned From the Treatment for All Initiative

Survey questionnaire on STI. surveillance, care and prevention. in European countries SAMPLE APPENDIX

BHIVA Satellite Symposium. Tougher Times: Adapting to Increasing Demand with Declining Resources

UK investment in HIV prevention 2015/16 and 2016/17. Examining UK expenditure on primary HIV prevention and HIV testing

Item 4. Sexual Health and Blood Borne Virus Strategy Strategy for Sexual Health and Blood Borne Viruses. Background

NAT submission to inquiry into the use of Immigration Detention

Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )

Program to control HIV/AIDS

HIV EPIDEMIC UPDATE: FACTS & FIGURES 2012

HIV in London: A Complexity Challenge

Strategic overview of sexual health procurement Haringey and London

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination

The HIV Prevention England programme: what s next? Cary James May 2016

Care Coach Collaborative Model Bridging Gap of Medical Linkage for HIV Positive Inmates Go home, kiss your Mother, and come into our offices. (Patsy F

Promoting the health and wellbeing of gay, bisexual and other men who have sex with men. Summary Document

Data: Access, Sources, and Systems

ONLY IN HUMANS! CAN GET SICK FASTER. What is HIV? NO CURE. Human Immunodeficiency Virus. HIV ATTACKS your T-cells. And uses them to of itself

National Survey of Young Adults on HIV/AIDS

OR: Steps you can take in the clinic to prevent HIV infections

Government of Canada Federal AIDS Initiative Milestones

HIV in Australia Annual surveillance short report 2018

Quality of medical services and their impact on the cascade of cares in HIV infection, at national level Roundtable discussion

Technical Guidance Note for Global Fund HIV Proposals

Sexually Transmitted Infection, including HIV, Health Protection Scotland Slide Set

Click to edit Master title style

HIV and AIDS Estimates

Modernization of North Carolina s HIV control measures

HCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report

WORLD AIDS DAY HIV in the UK Let s End It. World AIDS Day is celebrated annually on 1st December. Produced by NAT (National AIDS Trust)

Charles Boucher MD. PhD. HIV Prevention 2.0

HIV Treatment as Prevention (TasP) Guideline and protocol

Culturally Relevant Linkages to Care

Regional Collaboration to Optimize the Cascade: The Northwestern Public Health CFAR Consortium

Your Health Survey. Forename: Surname: Renal Unit: Type of treatment: If HD, are you: Date of birth: Home Post Code: Date completed: NHS number:

Source :

High Impact Prevention: Science, Practice, and the Future of HIV

Clinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States

Available In person Courses

Transcription:

HIV in the United Kingdom Valerie Delpech and Alison Brown on behalf of the HIV and AIDS Reporting Section National Infection Service Public Health England

Released 15 December 2017

Undetectable=Untransmittable ART is now so effective that those who are treated and have an undetectable viral load (<200 copies) have levels of virus that are untransmissible, even if having sex without condoms. This is sometimes referred to as U=U.

This year, there are 3 firsts in the 30 year history of the UK HIV epidemic..

In London, all the global UNAIDS 90:90:90 targets have been met with 90% of people living with HIV infection diagnosed, 97% of people diagnosed receiving treatment and 97% of those receiving treatment virally suppressed.

The continuum of HIV care by region of residence and risk group, England: 2016

HIV transmission among gay and bisexual men has fallen The observed decline in new diagnoses in gay and bisexual men is due to reduced transmission of HIV. The estimated annual number of new infections acquired in gay and bisexual men has declined year on year from a peak of around 2,800 (95% credible interval (CrI) 2,300 to 3,200) in 2012 to 1,700 (CrI 900 to 2,700) in 2016.

Geographical trends of new HIV diagnosis among gay and bisexual men: United Kingdom, 2007-2016

HIV diagnoses among gay and bisexual men, by population characteristics: England and London, 2007-2016

Estimates of HIV incidence in gay and bisexual men: using CD4 back-calculation, England

Trend in new MSM HIV diagnoses at STI clinics London & Outside London

HIV prevalence (diagnosed and undiagnosed)

Estimated number of people living with HIV (diagnosed and undiagnosed) all ages: England, 2016

Estimated number of people living with undiagnosed HIV infection by exposure and age group: England, 2015-2016

Estimates of undiagnosed HIV infection in gay and bisexual men using a CD4 back calculation method, England, 2007-2016

The death rate among people with HIV who are diagnosed promptly and on treatment is now comparable to the rest of the population Crude rates: 1.22 vs 1.39 per 1,000 population aged 15-59 yrs However, people diagnosed late remain at high risk of death 26.1 per 1,000 population aged 15 to 59 years in the first year of diagnosis.

One-year mortality (per 1,000) among adults newly diagnosed with HIV in 2015 by CD4 count at diagnosis: United Kingdom, 2015

Decline in new HIV diagnoses in heterosexual men and women There has been a continued decline in new HIV diagnoses among black African heterosexual men and women (4,060 in 2007 to 2,110 in 20163). This decline is due to changing patterns of migration, with fewer people from high HIV prevalence countries coming to the UK. However, among white heterosexual women and men new HIV diagnoses have remained relatively stable but low at around 750 per year over the past decade.

Values are adjusted for missing ethnicity New HIV diagnoses among heterosexuals by ethnicity: United Kingdom, 2007-2016

Number of new HIV diagnoses among heterosexual men and women, by region of diagnosis: UK, 2007-2016

Estimated number of new diagnoses probably acquired in the UK among heterosexual men and women, by country of birth: UK, 2007-2016

Estimated number of new diagnoses probably acquired abroad among heterosexual men and women, by country of birth: UK, 2007-2016

Challenges: reducing late diagnosis frequent testing

Adjusted for missing CD4 count at diagnosis. Adjusted number of people diagnosed late by exposure group: UK, 2007-2016

Number of gay/bisexual male attendees 16,000 14,000 12,000 HIV Testing Eligibility Cascade in gay & bisexual men of high risk (N= 14,650) attending services in London, 2015-16 100% *High-risk activity = bacterial STI diagnosis (excluding pharyngealonly infections) in a HIV negative 10,000 8,000 54% 51% 49% 6,000 4,000 2,000 54% 96% 95% 0 High risk MSM attendees in 2015 Did they return to the same clinic within 90-365 days? Were they offered at least one HIV test when they attended the clinic? How many attendees accepted at least one HIV test when they were offered? Presentation title - edit in Header and Footer

Number of High-risk MSM Number of HIV tests among gay & bisexual men of high risk in 2015 seen at the same STI clinic in 2016, London (n=7,117) 4,000 3,500 3,000 50% Recommendation: Men at high risk of HIV acquisition should be offered a test every 3 months 2,500 2,000 29% 1,500 1,000 500 0 14% 5% 1% 1 2 3 4 5+ Number of tests in 90 days after High-risk assessment Presentation title - edit in Header and Footer

Beyond viral suppression Monitoring Health and Wellbeing Quality of life and health inequalities 27 Positive Voices: The National Survey of People Living with HIV

Quality of Life EQ-5D-5L Below are some statements about your daily life and activities Please tick the box that best describes how you feel TODAY. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Mobility (walking) 74% 11% 10% 5% 0% Self-care (washing and dressing) 87% 5% 6% 1% 0% Usual Activities (e.g. work, study, housework, family or leisure activities) 72% 12% 10% 5% 1% Pain and Discomfort 54% 24% 12% 8% 2% Anxiety and Depression 51% 24% 16% 6% 3% None Slightly Moderately Severely Extremely Positive Voices: The National Survey of People Living with HIV

Mental health conditions Have you ever been diagnosed with any of the following... Depression 33% Anxiety 26% Sleep disorder/insomnia 15% Post-traumatic stress disorder Eating disorder Personality Disorder Psychosis or schizophrenia Bipolar disorder 5% 3% 2% 2% 2% Positive Voices: The National Survey of People Living with HIV

HIV and GP service experience Overall, on a scale from 0 to 10, how would you rate your GP/HIV clinic? GP services 6.9 HIV Patient experience measures The clinic provides enough information about my HIV I feel supported to self-manage my HIV I am involved in decisions about my HIV treatment and care At appointments, I feel I have enough time to cover everything I want to discuss The staff listen carefully to what I have to say 0% 20% 40% 60% 80% 100% 67% 65% 62% 67% 70% 31% 30% 32% 29% 27% 1% 0% 2% 1% 2% 1% 2% 3% 1% 2% 0% HIV services 9.2 GP Patient experience measures In my opinion, my GP knows enough about my HIV condition and treatment 24% 40%. 15% 8% 13% I am comfortable asking my GP questions about my HIV 25% 33% 19% 14% 9% My GP is as involved as I want them to be with my HIV care 24% 43% 13% 10% 11% As far as I am aware, my HIV specialist and my GP communicate well regarding my health 25% 39% 9% 7% 20% Strongly Agree Agree Disagree Strongly Disagree Don t know or Not applicable Positive Voices: The National Survey of People Living with HIV

Recommendations With progressive strengthening of combination prevention (including condom use, expanded HIV testing, prompt ART and availability of pre-exposure prophylaxis (PrEP)), HIV transmission AIDS and HIV-related deaths could be eliminated in the UK. The recent encouraging changes are dependent upon sustained prevention efforts. The inconsistencies between groups and geographies demonstrate that combination prevention needs to be replicated for all those at risk of acquiring of HIV, whoever they are and wherever they live. The HIV PrEP Impact Trial4 is a new component of PHE's HIV Prevention Programme. Beginning in October 2017, the 3-year trial5 of 10,000 participants will address outstanding questions on PrEP need, uptake and duration of use in those at high risk of HIV acquisition in England. Almost 200 sexual health clinics are being recruited as trial sites with 1,000 participants receiving PrEP by early November 2017. A new policy of immediate ART at HIV diagnosis is currently being considered by NHS England which would complement current Treatment as Prevention (TasP) policy. Swift implementation would ensure all people diagnosed with HIV achieve untransmissible levels of HIV. As people with HIV continue to age, it is critical that HIV and other services continue to evolve to meet the needs of people living with HIV including the management of comorbidities and other complex health conditions.

Recommendations: testing 1. Sexual health services should consider how they can ensure that: all gay and bisexual men are offered and recommended regular (ie annual) HIV tests all gay and bisexual men at high risk of HIV acquisition (eg a recent anogenital STI diagnosis), are offered and recommended frequent (ie every 3 months) HIV tests all black African men and women are offered and recommended regular HIV tests HIV partner notification improves for heterosexuals and gay and bisexual men all other attendees are offered and recommended to have HIV tests 2. General practices and secondary care in high and extremely high prevalence areas should consider how they can ensure that they offer and recommend HIV testing to patients in line with NICE recommendations. 3. Commissioners should consider how they can ensure that people at higher risk of HIV acquisition have access to a range of testing options including community testing and selfsampling. 4. Providers of health services to patients with hepatitis B and C, TB and people who inject drugs should consider how they can ensure that all patients are offered and recommended to have HIV tests. 5. Providers of HIV testing in prisons should consider how they can ensure that HIV testing is implemented and monitored effectively. 6. Antenatal service providers and blood, tissue and organ donation services should continue to maintain current high levels of HIV testing.

We celebrate these extraordinary findings which are the result of many years of work involving many key players and organisations from the whole HIV sector. By continuing to invest in effective preventative measures including condom use, expanded HIV testing, prompt treatment and the use of PrEP, HIV transmission, AIDS and HIV-related deaths could well be eliminated in the UK in the next few years.

HIV clinical dashboard Laura Waters & PHE HIV team (especially Zheng Yin)

HIV dashboard: a history Time Developed by Geography Details Past 2008-2012 Present 2013-present Future 2018 plus London HIV consortium Clinical Reference Group Clinical Reference Group London England England 1) % linkage to care after Dx 2) % ART coverage in pts with CD4 <350 3) % VL <200 among pts receiving ART for more than 12 months 4) One year mortality by CD4 at dx Nine indicators Time to treatment? Patient satisfaction measure from Positive Voices? 37 Time to treatment

National 2015 HIV Dashboard Indicators Description Late HIV diagnosis: Proportion of adults who were diagnosed at a late stage of HIV infection (CD4<350 cells/mm 3 ). Very late HIV diagnosis: Proportion of adults who were diagnosed at a very late stage of HIV infection (CD4<200 cells/mm 3 ). Newly diagnosed adults seen for care within 1 month: Proportion of newly diagnosed adults with an attendance date within one month of diagnosis date. Virological success in people established on ART: Proportion of adults achieving an undetectable viral load (<200 copies/ml) at least one year after starting ART. Virological success in people newly starting ART: Proportion of adults achieving an undetectable viral load (<200 copies/ml) between 6-12 months after starting ART. Proportion (%) 38% 21% 89% 95% 95% ART coverage (all adults): Proportion of adults seen for HIV care and receiving ART. 92% ART coverage (adults with the last CD4 count <350): Proportion of HIV diagnosed adults with last CD4<350 receiving ART. Retention in care (newly diagnosed): Proportion of newly diagnosed adults retained in care in the following year of diagnosis Retention in care (all adults): Proportion of adults retained in care in the following year Time to treatment 93% 88% 94%

Late HIV diagnosis

Men Pregnant women All other women 15-24 25-39 40-49 50+ White Black Other Ethnicity Heterosexual men Heterosexual women MSM PWID London Outside London Total Proportion of HIV diagnoses made at a late stage of infection*, by risk group: UK, 2016 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Sex Age group Ethnicity Exposure Region 40 *Adjusted for missing CD4 count at diagnosis.

1 7 13 19 25 31 37 43 49 55 61 67 73 79 4 10 16 22 28 34 40 46 52 58 64 70 76 82 88 94 100 4 10 16 5 11 17 23 41 Proportion of adults who were diagnosed at a late stage of HIV infection (CD4<350 cells/mm 3 ) *clinic size: number of people seen for care (sites that provide care) or number of diagnoses in last 10 years (non-care sites) 100% 90% Late HIV diagnosis 2015 by clinic size* National: 38% 80% 70% 0%-100% 0%-100% 18%-71% 60% 50% 18%-76% 40% 30% 20% 10% 0% <100 100-499 500-999 1000+

1 7 13 19 25 31 37 43 49 55 61 67 73 79 4 10 16 22 28 34 40 46 52 58 64 70 76 82 88 94 100 5 11 17 5 11 17 23 Very late HIV diagnosis 2015 by clinic size National:21% 100% 90% 80% 70% 60% 0%-100% 0%-100% 4%-61% 50% 40% 6%-35% 30% 20% 10% 0% <100 100-499 500-999 1000+ 42 Proportion of adults who were diagnosed at a very late stage of HIV infection (CD4<200 cells/mm 3 )

Newly diagnosed adults seen for care within 1 month

Men Women 15-24 25-34 35-49 50+ White Black African Other Gay/bisexual men Heterosexual men Heterosexual women PWID London Outside London Total Linkage to care: proportion of adults with a CD4 count within one and three months of diagnosis: UK, 2015 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Linked within 1 month Linked within 3 months Sex Age group Ethnicity Exposure Region 44

1 5 9 13 17 21 25 29 2 6 10 14 18 22 26 30 34 38 42 46 50 54 58 62 66 70 74 78 82 86 2 6 10 14 18 4 8 12 16 20 Newly diagnosed adults seen for care within 1 month by clinic size National: 89% 100% 90% 80% 70% 60%-100% 0%-100% 29%-100% 33%-100% 60% 50% 40% 30% 20% 10% 0% <100 100-499 500-999 1000+ 45 Proportion of newly diagnosed adults with an attendance date within one month of diagnosis

ART coverage

Sex Age group Ethnicity Exposure Region ART coverage among people accessing HIV care, UK, 2016 0% 20% 40% 60% 80% 100% Total Outside London London Gay/bisexual men Heterosexual women Heterosexual men PWID Black African White Other 15-24 25-34 35-49 50+ Women Men 96% 95% 97% 96% 96% 96% 93% 96% 96% 95% 89% 93% 96% 97% 95% 96%

1 6 11 16 21 26 31 36 41 46 51 56 2 7 12 17 22 27 32 37 42 47 52 57 62 67 72 77 82 87 1 6 11 16 3 8 13 18 ART coverage (all adults) by clinic size National: 92% 100% 90% 80% 70% 0%-100% 9%-100% 86%-96% 71%-100% 60% 50% 40% 30% 20% 10% 0% <100 100-499 500-999 1000+ 48 Proportion of adults seen for HIV care and receiving ART

1 6 11 16 21 26 31 36 41 46 51 2 7 12 17 22 27 32 37 42 47 52 57 62 67 72 77 82 87 1 6 11 16 3 8 13 18 ART coverage (adults with the last CD4 count <350) by clinic size National: 93% 100% 90% 80% 70% 60% 0%-100% 0%-100% 84%-99% 65%-100% 50% 40% 30% 20% 10% 0% <100 100-499 500-999 1000+ 49 Proportion of HIV diagnosed adults with last CD4<350 receiving ART

Virological success

100% Proportion of people receiving ART with virological suppression (<200 copies/ml: UK, 2012-2016 95% 90% 85% 2012 2013 2014 2015 2016 80% Gay and Heterosexual Heterosexual bisexual men men women PWID

1 6 11 16 21 26 31 36 41 46 51 56 4 9 14 19 24 29 34 39 44 49 54 59 64 69 74 79 84 89 3 8 13 18 5 10 15 20 100% 90% 80% 70% Virological success in people established on ART by clinic size National: 95% 69%-99% 67%-100% 86%-100% 89%-99% 60% 50% 40% 30% 20% 10% 0% <100 100-499 500-999 1000+ 52 Proportion of adults achieving an undetectable viral load (<200 copies/ml) at least one year after starting ART

1 6 11 16 21 26 31 2 7 12 17 22 27 32 37 42 47 52 57 62 67 72 77 82 87 4 9 14 1 6 11 16 100% Virological success in people newly starting ART by clinic size National: 95% 90% 80% 70% 0%-100% 29%-100% 80%-100% 81%-100% 60% 50% 40% 30% 20% 10% 0% <100 100-499 500-999 1000+ 53 Proportion of adults achieving an undetectable viral load (<200 copies/ml) between 6-12 months after starting ART

Retention in care

1 6 11 16 21 26 31 36 41 46 4 9 14 19 24 29 34 39 44 49 54 59 64 69 74 79 84 89 3 8 13 18 5 10 15 20 100% Retention in care (newly diagnosed) by clinic size National: 88% 90% 80% 70% 60% 0%-100% 0%-100% 59%-100% 76%-96% 50% 40% 30% 20% 10% 0% <100 100-499 500-999 1000+ 55 Proportion of newly diagnosed adults retained in care in the following year of diagnosis

1 7 13 19 25 31 37 43 49 55 61 67 4 10 16 22 28 34 40 46 52 58 64 70 76 82 88 3 9 15 3 9 15 21 100% Retention in care (all adults) by clinic size National: 94% 90% 80% 86%-97% 70% 60% 0%-100% 72%-98% 87%-98% 50% 40% 30% 20% 10% 0% <100 100-499 500-999 1000+ 56 Proportion of adults retained in care in the following year

NHSE PHE 2016 HIV dashboard process and timeline Process 2016 HIV data released HIV report published Deadline October 2017 November 2017 HIV dashboard indicators produced and checked (site level) December 2017 Dashboard summary and follow-up sent to clinics for review January 2018 HIV dashboard indicators finalised and sent to NHSE/Methods (trust level) February 2018 HIV Dashboard indicators published on Methods SSQD web portal to gatekeeper at each trust for review March 2018 HIV dashboard indicators finalised and published on SSQD web portal April 2018 (provisional) 57

Time to treatment

59 Delay to HIV treatment initiation

Time to treatment among patients newly diagnosed with HIV: UK, 2011-2016

Proportion of patients newly diagnosed starting ART within 90 days of diagnosis, by anonymised HIV services: UK, 2016

A new indicator?

Voting question Should we have a time to treatment indicator for newly diagnosed people? Yes No Don't know

Time to treatment What should the indicator be? 90% by 48 hours 90% by 30 days 90% by 90 days Other

Acknowledgements We gratefully acknowledge the continuing collaboration of people living with HIV, as well as clinicians, microbiologists, immunologists, public health practitioners, occupational health doctors, nurses and other colleagues who contribute to the surveillance of HIV and STIs in the UK.